Desmopressin vs Vasopressin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicDesmopressinVasopressin
What it is

A synthetic analogue of the pituitary hormone arginine vasopressin with stronger antidiuretic and weaker blood-pressure effects, according to the DDAVP label.1

A synthetic polypeptide hormone, arginine vasopressin, that acts on V1 receptors in blood vessels and V2 receptors in the kidney, according to the label.3

FDA status

FDA-approved

FDA-approved as DDAVP for diabetes insipidus and bedwetting1,2

FDA-approved. Drugs@FDA lists DDAVP, NDA 019955, with an original approval date of September 6, 1995. The cited label has no boxed warning.1,2

Is desmopressin FDA-approved?

FDA-approved

FDA-approved as Vasostrict for vasodilatory shock3,4

FDA-approved. Drugs@FDA lists Vasostrict with an original approval date of April 17, 2014. The cited label has no boxed warning.3,4

Is vasopressin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Desmopressin is not among them.5,6

Not among the six peptides the policy lists.5

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Two double-blind, randomized, placebo-controlled trials in 340 patients aged 5 to 17 with primary nocturnal enuresis, pooled in the label.1
  • Small, short, or incompletely reported human study Four long-term studies in which 46 patients with central diabetes insipidus took DDAVP for 12 to 44 months, described in the label.1

Limited human data

  • Small, short, or incompletely reported human study Seven studies in septic shock and eight in vasodilatory shock after heart surgery, in which systolic and mean blood pressure rose, summarized in the label without design or size.3
Records collected

25 ClinicalTrials.gov records and 25 PubMed records collected

30 ClinicalTrials.gov records and 30 PubMed records collected

Area of study

Hormones1

Heart and blood vessels3

Latest dated events
  1. DailyMed publishes the DDAVP label version cited on this page.1
  2. FDA approves the DDAVP application cited here, NDA 019955, according to Drugs@FDA.2
  1. DailyMed publishes the Vasostrict label version cited on this page.3
  2. FDA approves Vasostrict, according to Drugs@FDA.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    DDAVP (desmopressin acetate) tablet · SPL version 7 · published 2025-12-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: DDAVP (desmopressin acetate), NDA 019955 · original approval September 6, 1995 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    VASOSTRICT (vasopressin) injection · SPL version 49 · published 2026-05-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: VASOSTRICT (vasopressin), NDA 204485 · original approval April 17, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026